AXL and neoplasm: Sitravatinib has recently been shown to inhibit MET in mesothelioma and lung cancers, PDGFRs in sarcomas [17, 18], and select TAM (TYRO3, AXL, MerTK) receptors in tumor associated macrophages, amongst several other receptor families [19, 20].